一例罕见的索拉非尼诱发的严重低钠血症病例。
A rare case of sorafenib-induced severe hyponatremia.
作者信息
Khaja Misbahuddin, Torchon Frantz, Millerman Konstantin
机构信息
Division of Pulmonary/Critical Care Medicine, Bronx Care Health System, Icahn School of Medicine at Mount Sinai, Bronx, NY, USA.
Division of Critical Care Medicine, New York-Presbyterian Lawrence Hospital Center, Columbia University Vagelos College of Physicians and Surgeons, Bronxville, NY, USA.
出版信息
SAGE Open Med Case Rep. 2019 Apr 28;7:2050313X19846048. doi: 10.1177/2050313X19846048. eCollection 2019.
BACKGROUND
Sorafenib is an anti-angiogenic tyrosine kinase inhibitor used to treat patients with renal cell cancer and advanced hepatocellular cancer. Common adverse effects of sorafenib are rash, diarrhea, nausea, and abnormal liver function test and hand-foot syndrome.
CASE PRESENTATION
Here, we present a case of a 90-year-old male who was prescribed sorafenib after being diagnosed with hepatocellular cancer. At 1 week after sorafenib initiation, he was admitted to the emergency room for an evaluation of weakness. The patient had hyponatremia, a common electrolyte abnormality seen in cancer patients. His hyponatremia improved when the sorafenib was stopped, suggesting that this was a rare case of hyponatremia induced by sorafenib.
CONCLUSION
Although sorafenib is used in the treatment of hepatocellular cancer, it can cause life-threatening complication such as hyponatremia. Early identification of the cause of hyponatremia can prevent serious adverse event.
背景
索拉非尼是一种抗血管生成酪氨酸激酶抑制剂，用于治疗肾细胞癌和晚期肝细胞癌患者。索拉非尼的常见不良反应包括皮疹、腹泻、恶心、肝功能检查异常和手足综合征。
病例介绍
在此，我们报告一例90岁男性患者，在被诊断为肝细胞癌后服用索拉非尼。在开始服用索拉非尼1周后，他因乏力入院急诊评估。该患者患有低钠血症，这是癌症患者中常见的电解质异常。停用索拉非尼后，他的低钠血症得到改善，提示这是一例罕见的由索拉非尼引起的低钠血症。
结论
尽管索拉非尼用于治疗肝细胞癌，但它可导致危及生命的并发症，如低钠血症。早期识别低钠血症的病因可预防严重不良事件。
Zotero 插件